agitg trial news

Trial Recruitment

AGITG Trial news: The AGITG currently has 18 studies open to recruitment and 9 studies in follow up.

The table below details the AGITG trials that are currently accruing patients.

Recruited Target Date of First Site Open (ANZ) Number of Sites Open  End of Recruitment 
ASCEND (Pancreatic cancer) 9 125 13 April 2022 10 October 2023
DYNAMIC-III (Colon cancer) 836 1000 09 October 2017 43  December 2023
DYNAMIC-Pancreas (Pancreatic cancer) 114 438 01 March 2019 26 August 2023
GENESCREEN 5-FU (Pan Tumour) 75 100 1 February 2021 4 April 2025
ICEMELT (Gastrointestinal) 107 200 9 December 2020 2 November 2025
INTEGRATE IIb (Gastro-oesophageal cancer) 187 450 28 April 2021 21 April 2023
LICPIC (Colorectal cancer) 99 100 11 September 2018 2 September 2024
MASTERPLAN (Pancreatic cancer) 31 120 01 October 2019 11 October 2023
MASTERPLAN Microbiome (Pancreatic cancer) 2 60  July 2022 2 February 2024 
NEO-IMPACT (Pancreatic cancer) 0 20 13 May 2022 3 May 2024
OXTOX (Colorectal cancer) 15 100 18 December 2020 9 December 2023
PALEO (Oesophageal cancer) 3 54 3 December 2021 1 May 2023
RANDOMS (Pancreatic cancer) 10 60 14 December 2020 3 February 2024
RENO (Rectal cancer) 58 125 21 January 2019 9 January 2024
RESOLUTE  (Colorectal Cancer) 0 75 14 December 2021 4 June 2023
RoLaCaRT-1  (Colorectal Cancer) 17 50 06 August 2021 10 December 2022
SPAR (Rectal cancer) 103 222 13 April 2018 15 December 2022
SSGXXII (Colorectal Cancer) 4 25-30 17 February 2022 7 March 2023

 

Share